Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Reinventing Flexion For The World Beyond Proof-Of-Concept

Mar 15 2013

Related Content

Knee OA: Growing Demand For Nonsurgical Options

Dec 16 2011

No Longer Aiming To Partner At Proof-of-Concept, Flexion Raises $20M For Late-Stage Trials

Dec 04 2012

With Pharma Ready to Pare Portfolios, Project Financing Funds Make Their Pitches

Jun 01 2010

Flexion Exploits Big Pharma as Discovery Supplier

Jan 01 2010

IND Over POC: The New Sweet Spot For Biopharma Dealmaking

Oct 01 2011

Flexion: The In-Licensing Advantage of Cheap Proof-of-Concept

Dec 01 2007

Related Companies

Flexion Therapeutics, Inc.

Eli Lilly and Company

Eli Lilly and Company

Bristol Myers Squibb Company

Merck KGaA

AstraZeneca PLC

Clovis Oncology, Inc.

Intarcia Therapeutics, Inc.

Smith & Nephew plc

Zimmer Biomet Holdings, Inc.

Sanofi

Sanofi Genzyme

Additional Topics

Strategy Business Strategies Clinical Trials Deals Research & Development BioPharmaceutical

More from Business Strategy

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window